BioHarvest Sciences (NASDAQ:BHST) Shares Down 1.1% – Here’s Why

BioHarvest Sciences Inc. (NASDAQ:BHST) shares fell 1.1% on Thursday . The stock traded as low as $4.65 and last traded at $4.65. 18,552 shares changed hands during trading, a decline of 51% from the average session volume of 37,636 shares. The stock had previously closed at $4.70.

Wall Street Analysts Forecast Growth

Several equities analysts have recently commented on the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of BioHarvest Sciences in a report on Monday, December 29th. Wall Street Zen upgraded BioHarvest Sciences to a “hold” rating in a research note on Saturday, October 18th. Two investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, BioHarvest Sciences has a consensus rating of “Hold” and a consensus price target of $14.50.

BioHarvest Sciences Stock Performance

The company has a market cap of $76.35 million, a P/E ratio of -6.84 and a beta of 1.12. The company has a quick ratio of 1.02, a current ratio of 1.35 and a debt-to-equity ratio of 0.30. The company has a 50 day moving average price of $5.38 and a 200-day moving average price of $7.63.

BioHarvest Sciences (NASDAQ:BHST) last released its earnings results on Thursday, November 13th. The company reported ($0.14) EPS for the quarter, meeting the consensus estimate of ($0.14). The firm had revenue of $9.07 million for the quarter, compared to analysts’ expectations of $9.11 million. BioHarvest Sciences had a negative net margin of 36.33% and a negative return on equity of 1,041.86%. Equities analysts expect that BioHarvest Sciences Inc. will post -0.8 EPS for the current fiscal year.

Institutional Investors Weigh In On BioHarvest Sciences

A hedge fund recently raised its stake in BioHarvest Sciences stock. True North Advisors LLC grew its holdings in shares of BioHarvest Sciences Inc. (NASDAQ:BHST) by 676.1% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 168,013 shares of the company’s stock after purchasing an additional 146,365 shares during the period. True North Advisors LLC owned approximately 1.02% of BioHarvest Sciences worth $1,581,000 as of its most recent filing with the Securities and Exchange Commission.

About BioHarvest Sciences

BioHarvest Sciences Inc is a biotechnology company that specializes in the development and commercialization of plant-based active ingredients through proprietary cell-culture technology. By growing undifferentiated plant cells in controlled bioreactor environments, the company aims to produce full-spectrum phytonutrients and botanical compounds that are difficult to obtain through traditional farming methods. This approach is designed to deliver consistent, high-purity extracts with reduced environmental impact and supply-chain variability.

The company’s product portfolio focuses on applications across the cosmeceutical, nutraceutical and health-and-wellness markets.